Radiopharmaceuticals and Tracers

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017

August 16, 2017 — In the featured translational article in the August issue of ...

PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017

July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...

Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017

July 7, 2017 — Blood clots in veins...

Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017

June 20, 2017 — Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F...

Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017

May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced...

FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017

May 15, 2017 — Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be...

Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017

April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the...

News | Prostate Cancer | April 24, 2017

April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal...

University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017

April 13, 2017 — The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA...

IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017

April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...

GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017

April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization...

News | Radiopharmaceuticals and Tracers | March 29, 2017

March 29, 2017 — Advanced Accelerator Applications S.A. announced that its product NETSPOT (gallium Ga-68 dotatate)...

PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

News | Radiopharmaceuticals and Tracers | March 16, 2017

March 16, 2017 — The featured clinical investigation article of the March 2017 issue of the ...

Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers | March 10, 2017 | Anamika Kumari

Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial...

X0000_Piramal_Neuraceq PET agent_beta amyloid plaque imaging.jpg
News | Radiopharmaceuticals and Tracers | March 09, 2017

March 9, 2017 — Piramal Imaging SA and Isologic Innovative Radiopharmaceuticals recently announced that Health...

Navidea, Lymphoseek, North American rights, sale, Cardinal Health
News | Radiopharmaceuticals and Tracers | March 08, 2017

March 8, 2017 — Navidea Biopharmaceuticals announced the completion of the sale of its Lymphoseek product to...

PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017

March 3, 2017 — In the featured article of the March 2017 issue of...

News | Radiopharmaceuticals and Tracers | February 16, 2017

February 16, 2017 — Cerveau Technologies Inc. announced it has signed an agreement with Siemens’ PETNET Solutions...

Blue Earth Diagnostics, Axumin, fluciclovine F-18, recurrent prostate cancer, Simens PETNET Solutions, increased patient access
News | Radiopharmaceuticals and Tracers | February 07, 2017

February 7, 2017 — Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of...

radiotargeted therapy, SST2 antagonists, combat cancer, neuroendocrine tumors, NETs, Journal of Nuclear Medicine study

Comparative receptor autoradiography in various cancer types (A = HE staining) with I-125-JR11 (B+C) and I-125-Tyr3-octreotide (D+E). B and D are the respective total binding, C and E the respective non-specific binding. Bars = 1 mm.

I: Breast cancer. II: Renal cell cancer. III: Medullary thyroid cancer. IV: Non-Hodgkin lymphoma. V: Colon cancer. In cancers I-V, the sections were incubated with 30’000 cpm/100 μl of antagonist or agonist. Cancers I-IV show a much higher density of sst2 with the antagonist. The colon cancer V is negative. VI: Ileal NET, incubated with 10’000 cpm/100 μl of antagonist or agonist. Credit: Jean Claude Reubi, Institute of Pathology, University of Berne, Berne, Switzerland. 

News | Radiation Therapy | February 06, 2017

February 6, 2017 — A study published in the February issue of...

Overlay Init